Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2011: Review Article  

Magnetic resonance in studies of glaucoma

Michal Fiedorowicz , Wojciech Dyda , Robert Rejdak , Pawel Grieb

DOI: 10.12659/MSM.881973

Med Sci Monit 2011; 17(10): RA227-232

0 Comments

Abstract

ABSTRACT: Glaucoma is the second leading cause of blindness. It affects retinal ganglion cells and the optic nerve. However, there is emerging evidence that glaucoma also affects other components of the visual pathway and visual cortex. There is a need to employ new methods of in vivo brain evaluation to characterize these changes. Magnetic resonance (MR) techniques are well suited for this purpose. We review data on the MR evaluation of the visual pathway and the use of MR techniques in the study of glaucoma, both in humans and in animal models. These studies demonstrated decreases in optic nerve diameter, localized white matter loss and decrease in visual cortex density. Studies on rats employing manganese-enhanced MRI showed that axonal transport in the optic nerve is affected. Diffusion tensor MRI revealed signs of degeneration of the optic pathway. Functional MRI showed decreased response of the visual cortex after stimulation of the glaucomatous eye. Magnetic resonance spectroscopy demonstrated changes in metabolite levels in the visual cortex in a rat model of glaucoma, although not in glaucoma patients. Further applications of MR techniques in studies of glaucomatous brains are indicated.

Keywords: Myelin Sheath - pathology, Manganese, Magnetic Resonance Spectroscopy - methods, Magnetic Resonance Imaging - trends, Glaucoma - pathology, Diffusion Tensor Imaging - methods, Axonal Transport - physiology, Optic Nerve - physiopathology, Visual Cortex - pathology

Background

Glaucoma is the second leading cause of blindness worldwide [1]. Moreover, in contrast to cataract, which is the leading cause of blindness, blindness caused by glaucoma is irreversible. Since progression of the disease is prolonged and may remain unnoticed for many years, it has been referred to as a ‘sneaky thief of sight’.

In fact, the term glaucoma describes a group of diseases with varying etiologies, which have 2 common clinical features [2]: glaucomatous pattern of visual field loss [3] and optic nerve neuropathy resulting in ‘optic disc cupping‘ (increased cup/disc ratio) [4]. The disease is classified as ‘primary’ if there are no signs of ocular pathology that elevate intraocular pressure (IOP) above the normal range (role of the elevated IOP in glaucoma is described in the next paragraph), or ‘secondary’ if such a pathology is identified. Secondary glaucomas are further subdivided according by the type of the primary pathology (eg, uveitic, neovascular, traumatic, pseudoexfoliation glaucomas) [5]. There are also developmental glaucomas. Another subdivision of glaucoma depends on whether the drainage angle is open (open angle glaucoma) or closed (closed angle glaucoma) [6]. The most frequent type is ‘primary open angle glaucoma‘ (POAG).

Formerly the definition of human glaucoma included elevation of IOP over the upper limit of the normal range (most frequently >21 mmHg). However, many individuals with elevated IOP will never develop glaucoma (this apparently benign condition is termed ‘intraocular hypertension’), and quite a few people suffer from glaucoma while measurements of their IOP never exceed 21 mmHg (this condition is called ‘normal tension glaucoma’, NTG). Diagnosis of elevated IOP is therefore neither sufficient nor necessary to diagnose glaucoma; however, it is still regarded as a major risk factor for this disease. Elevated IOP might affect axonal transport, retrograde as well as anterograde, within the optic nerve [7,8]. This disturbs delivery of neurotrophic factors such as BDNF and its receptor, TrκB, which may be required for survival of retinal ganglion cells (RGC) [9,10].

An interesting hypothesis has been proposed according to which the etiopathologic factor is not the high IOP but the difference between IOP and intracranial pressure (ICP) [11]. The optic nerve is exposed to considerable forces acting across the lamina cribrosa. In a normal eye the lamina, which is 450 μm thick, is exposed to a pressure gradient of 4 mmHg, which is one of the highest pressure gradients that any nerve in the body is constantly exposed to [11]. Moreover, some studies have shown that in patients with glaucoma ICP is lower [11], whereas the lamina cribrosa is thinner [12], which means that their optic nerve is exposed to a higher damaging pressure [13]. This mechanism may explain the phenomenon of normal tension glaucoma. In animal experiments, Yablonski et al. [14] (observations published only in abstract form) found that chronic lowering of intracranial pressure led to glaucomatous damage of the optic nerve, and that simultaneous lowering of IOP prevented this damage.

In the human retina, glaucoma mainly affects the RGC layer, and selective RGC death is regarded as the hallmark of glaucoma [15–17]. There are several proposed mechanisms of this selective cell death, including excitotoxicity [18], nitric oxide toxicity [19], oxidative stress [20,21] and trophic factors deficiency [22].

Although glaucoma is commonly considered as a retinal disease, there is substantial evidence that not only RGC and the optic nerve, but also upstream components of the visual pathway and visual cortex are affected [23]. Detailed information on how different components of the visual pathway are affected in glaucoma can be obtained with modern imaging techniques, in particular magnetic resonance imaging (MRI) and spectroscopy (MRS). Advances in visualizing visual pathways in the context of glaucoma were thoroughly reviewed by Garaci et al. [24]. Here, we focus on novel results concerning use of MR techniques in the field of glaucoma research.

Magnetic Resonance Imaging (MRI) in Studies of Glaucoma

MRI makes it possible to visualize the bony structures of the skull including orbit, orbital apex, optic canal, as well as intraorbital masses, oculomotor muscles and retrobulbar adipose tissue. Moreover, the bulb of the eye, the lens inside it, optic nerve, sheath, optic chiasm, tracts and radiations can be visualized [25]. While the optic nerve and optic chiasm can be seen quite easily, other parts of the visual pathway may be more difficult to distinguish on MR images and may require more advanced techniques, as discussed later. Generally the ability to see the structure on MR image is based on the difference in signal strength between them and the surrounding tissue, for example between nerves and cerebrospinal fluid or between white and gray matter.

The optic nerve is a white-matter tract, which in the intraorbital part is surrounded by adipose tissue. This fat is characterized by high signal intensity, which makes the optic nerve easily discernible on MR images. Glaucoma leads to loss of neurons, and its progression can be observed through measuring the diameter of the optic nerve. Thinning of the optic nerve visible on MR images was most pronounced 15 mm behind the bulb and showed correlation with retinal nerve fiber layer thickness measured using optic coherence tomography [26]. The other MRI study also showed that the optic nerve diameter was significantly smaller in glaucoma patients (2.25 mm) in comparison with the control group (2.47 mm) [27].

The optic chiasm is surrounded by cerebrospinal fluid in the chiasmatic cistern, which makes it highly visible. Changes in the optic chiasm in glaucoma reflect the decreased number of axons in the optic nerve. The optic chiasm was atrophic and its height was shorter in patients with glaucoma, especially when huge visual field defects were present [27,28]. Correlation between the height of the optic chiasm and visual field defects was even stronger than the correlation between vertical cup-disc (VC/D) ratio (which is the basic parameter for assessing the progression of glaucoma) and visual field defects [28].

Despite the relatively poor sensitivity and resolution of the technique and small thickness of the retina, it is also possible to investigate the retina and its neural connections with MRI (Figure 1). Such studies can be performed using manganese as the dedicated contrast agent; the technique is called MEMRI (manganese-enhanced MRI). Mn2+ ions are paramagnetic and sites of their accumulation can be visualized by MRI because they shorten the T1 relaxation time of the surrounding water protons, resulting in positive enhancement of the MR signal. Manganese ions, which behave as analogues of calcium ions, enter intraneuronal space by 2 mechanisms – through calcium voltage-gated channels during activation of neuronal cell and by specific metal ion transporters without concomitant electrical activity. Moreover, they are transported down axons via microtubule-based fast axonal transport and are able to cross synaptic clefts [29]. In rats, Mn+2 injected intraocularly were taken up by RGCs and transported along microtubules in the optic nerve, and further through chiasms to the contralateral optic tract, the dorsal and ventral lateral geniculate nucleus, the superior colliculus and its brachium, the olivary pretectal nucleus, the nucleus of the optic tract, and the suprachiasmatic nucleus [30]. When MnCl2 was administered systemically during a visual task, it acted as a functional biomarker of intraretinal ion regulation [31]. Moreover, thickness of the retina layers measured with high-resolution MEMRI technique is similar to the histopathological findings. This technique was also used to assess changes in glaucomatous eyes in animal models [32]. One study showed accumulation of Mn2+ ions in the vitreous, retina and optic nerve head in a glaucomatous eye of a rat after intravitreal injection (Figure 1) [33]. Concentration of Mn2+ ions was higher in the glaucomatous eye than in the control eye, which could have been a reflection of decreased number of RGC cells, reduction in axonal density of the optic nerve and blockage of axoplasmic transport along the optic nerve [34].

MnCl2 is not approved for humans, but there is another manganese-based contrast agent that is already used in humans – Mangafodipir (sold under brand name Teslascan) contains Mn2+ ions chelated by fodipir and is mainly used as a contrast agent in imaging of the liver and allows discrimination of tumors and healthy hepatic tissue [35]. Some recent studies also have shown that mangafodipir is useful as a contrast agent in imaging of retina and visual pathways in animal studies [36,37].

Diffusion MRI

Diffusion of water molecules in tissues does not proceed equally in all directions – usually movement in 1 direction is predominant. Studies of water diffusivity provide information on cellular integrity, especially the integrity and connectivity of the white matter. Conventional MRI provides little information on diffusivity; however, as diffusing protons move through intrinsic and extrinsic field gradients they lose transverse magnetization. This phenomenon is used to create diffusion maps [38]. There are 2 subtypes of diffusion MRI – diffusion-weighted MRI (DW MRI) and diffusion tensor MRI (DT MRI). DW MRI applies when the observed tissue is dominated by isotropic water movement, and DT MRI applies when the tissue is dominated by anisotropic water movement. One application of DT MRI is tracking the nerve fibers (so called tractography). This technique can be used to visualize inter alia optic tract [39].

Hui et al. [40], using DT MRI, showed that in a rat model of ocular hypertension induced by laser photocoagulation of the episcleral and limbal veins, DT MRI-derived parameters (ie, radial diffusivity and fractional anisotropy) were affected in the optic nerve. Radial diffusivity was increased and fractional anisotropy decreased, suggesting that axonal density was reduced by around 10% when compared to control rats. Moreover, the authors performed DT MRI at various time points after photocoagulation and showed that radial diffusivity was increasing and fractional anisotropy was decreasing over time. These results were confirmed by histological evaluation of the optic nerve. Garaci et al. [41] reported similar findings in patients with POAG. Mean diffusivity was increased and correlated with the stage of glaucomatous optic neuropathy, while fractional anisotropy was decreased and also correlated with the stage of glaucoma (Figure 2).

Functional Imaging

Functional MRI (fMRI) was a breakthrough in the imaging of the brain. This technique, known also as BOLD (blood oxygen level-dependent) imaging is based on observation of changes of the local cerebral hemodynamics accompanying changes in neural activity. Increased cerebral activity is followed by increase in blood flow, resulting in local lowering of deoxyhemoglobin to oxyhemoglobin ratio, because increased blood flow delivers more oxyhemoglobin than is needed. This allows visualizing brain activation locally using MR.

In particular, local changes in oxygenation of hemoglobin in the visual cortex corresponded with the visual stimulation of the eye, which made it possible to prepare a map of the cortical representation of the retina. Further study was performed to find the relationship between visual field loss in POAG (as measured with a standard automated perimetry) and visual cortex (V1) activation pattern evoked by a scotoma-mapping stimulus and measured with fMRI in unilateral glaucoma [42]. In that study it was found that altered patterns of neuronal activity in POAG were consistent with visual field deficits.

However, fMRI indices of altered visual cortex functional response in POAG may not have a simple and direct relation to the glaucomatous degeneration of the visual cortex. Recently, Qing et al. [43] used fMRI to investigate the impact of the glaucomatous neuropathy on the central normal visual field. These authors measured BOLD fMRI changes in the glaucomatous eyes with asymmetric peripheral visual field damage, but without changes in central vision. BOLD signals corresponding to the central vision field in the primary visual cortex were decreased in comparison to the signals from the non-glaucomatous eyes, despite the fact that there were no changes in patients’ central visual fields.

MR Spectroscopy

Magnetic resonance spectroscopy (MRS) is the technique that enables non-invasive assessment of levels of resonance-visible metabolites in situ. In this technique measurements of areas under metabolite resonances in a magnetic resonance spectrum are directly proportional to the concentration of these metabolites. Although MR spectra can be recorded for various nuclei (eg, phosphorus, fluorine, carbon 13C), in biomedical research proton (1H) resonance spectra are of particular interest. The 3 most prominent resonance lines in the proton MR spectrum of the brain are those related to creatine and phosphocreatine (Cr, involved in cellular energy metabolism), choline compounds (Cho, associated with metabolism of cell membranes and involved in cholinergic transmission), and N-acetyl aspartate (NAA, considered to be the marker of neuronal integrity). Brain 1H MRS data are frequently reported as the metabolite ratios (NAA/Cr, Cho/Cr, etc.). More advanced MRS paradigms allow calibration of resonance signals in terms of molar concentrations [44] and record up to 17 brain metabolites in animal experiments [45].

Although 1H MRS has many potential clinical applications in the area of neurodegenerative diseases (eg, Parkinson’s [46], Alzheimer’s disease [38], and multiple sclerosis [47]), this technique has been rarely used in glaucoma studies. Chan et al. [48] recorded 1H MR spectra in a rat model of ocular hypertension induced by photocoagulation of episcleral and limbal veins with an argon laser. Six weeks after initiation of intraocular hypertension, they found decreased Cho/Cr ratio in the visual cortex suggestive of a dysfunction in the cholinergic system of the visual pathway (Figure 3). However, Boucard et al. [49] could not detect statistically significant differences of NAA, Cr and Cho resonance signals in patients with POAG compared to non-glaucomatous controls. Different results from the animal and human studies may reflect a difference between the acute animal models (where quick degeneration is observed) and prolonged degeneration in humans subjects.

Ngumah et al. [50] also used MRS to analyze changes in lactate concentration in vitreous after induction of ocular hypertension in rabbits. They found a good correlation between rise in IOP and increased lactate signal. Performing localized MRS in the vitreous can be a useful tool in tracking pathological changes in experimental models of glaucoma and in human disease.

Conclusions

Glaucoma is a neurodegenerative disease that affects structure and functioning of the retina and optic nerve, and has an impact on morphology of chiasms and optic radiation. The function of the visual cortex is also affected, as revealed by fMRI. Changes in the optic nerve and visual cortex correlate with the progression of glaucoma. MR techniques seem to be useful tools for characterization of glaucoma-related changes in the visual pathway both in laboratory animals and in humans, and may prove useful as tools for monitoring the progression of glaucoma and assessing the efficacy of novel treatment strategies.

References

1. Resnikoff S, Pascolini D, Etya’ale D, Global data on visual impairment in the year 2002: Bull World Health Organ, 2004; 82; 844-51, pmid: 15640920

2. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ, The definition and classification of glaucoma in prevalence surveys: Br J Ophthalmol, 2002; 86; 238-42, pmid: 11815354

3. Kitazawa Y, Yamamoto T, Glaucomatous visual field defects: their characteristics and how to detect them: Clin Neurosci, 1997; 4; 279-83, pmid: 9292256

4. Alexander KL, Glaucomatous cupping – appearance, pathogenesis, detection: J Am Optom Assoc, 1978; 49; 1056-59, pmid: 701722

5. Leszczynski R, Domanski R, Forminska-Kapuscik M, Contact transscleral cyclophotocoagulation in the treatment of neovascular glaucoma: a five-year follow-up: Med Sci Monit, 2009; 15(3); BR84-87, pmid: 19247237

6. Cheng JW, Li P, Wei RL, Meta-analysis of association between optineurin gene and primary open-angle glaucoma: Med Sci Monit, 2010; 16(8); CR369-77, pmid: 20671613

7. Anderson DR, Hendrickson A, Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve: Invest Ophthalmol, 1974; 13; 771-83, pmid: 4137635

8. Quigley H, Anderson DR, The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve: Invest Ophthalmol, 1976; 15; 606-16, pmid: 60300

9. Pease ME, McKinnon SJ, Quigley HA, Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma: Invest Ophthalmol Vis Sci, 2000; 41; 764-74, pmid: 10711692

10. Quigley HA, McKinnon SJ, Zack DJ, Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats: Invest Ophthalmol Vis Sci, 2000; 41; 3460-66, pmid: 11006239

11. Berdahl JP, Allingham RR, Intracranial pressure and glaucoma: Curr Opin Ophthalmol, 2010; 21; 106-11, pmid: 20040876

12. Jonas JB, Berenshtein E, Holbach L, Lamina cribrosa thickness and spatial relationships between intraocular space and cerebrospinal fluid space in highly myopic eyes: Invest Ophthalmol Vis Sci, 2004; 45; 2660-65, pmid: 15277489

13. Ren R, Jonas JB, Tian G, Cerebrospinal fluid pressure in glaucoma: a prospective study: Ophthalmology, 2010; 117; 259-66, pmid: 19969367

14. Yablonski ME, Ritch R, Pokorny KS, Effect of decreased intracranial pressure on optic disc: Invest Ophthalmol, 1979; 18; 165

15. Kaushik S, Pandav SS, Ram J, Neuroprotection in glaucoma: J Postgrad Med, 2003; 49; 90-95, pmid: 12865582

16. Naskar R, Dreyer EB, New horizons in neuroprotection: Surv Ophthalmol, 2001; 45(Suppl 3); S250-55, pmid: 11377444 discussion S273–76

17. Wein FB, Levin LA, Current understanding of neuroprotection in glaucoma: Curr Opin Ophthalmol, 2002; 13; 61-67, pmid: 11880717

18. Casson RJ, Possible role of excitotoxicity in the pathogenesis of glaucoma: Clin Experiment Ophthalmol, 2006; 34; 54-63, pmid: 16451260

19. Neufeld AH, Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma: Brain Res Bull, 2004; 62; 455-59, pmid: 15036557

20. Izzotti A, Bagnis A, Sacca SC, The role of oxidative stress in glaucoma: Mutat Res, 2006; 612; 105-14, pmid: 16413223

21. Ohia SE, Opere CA, Leday AM, Pharmacological consequences of oxidative stress in ocular tissues: Mutat Res, 2005; 579; 22-36, pmid: 16055157

22. Cohen-Cory S, Lom B, Neurotrophic regulation of retinal ganglion cell synaptic connectivity: from axons and dendrites to synapses: Int J Dev Biol, 2004; 48; 947-56, pmid: 15558485

23. Gupta N, Yucel YH, What changes can we expect in the brain of glaucoma patients?: Surv Ophthalmol, 2007; 52(Suppl 2); S122-26, pmid: 17998036

24. Garaci FG, Cozzolino V, Nucci C, Advances in neuroimaging of the visual pathways and their use in glaucoma: Prog Brain Res, 2008; 173; 165-77, pmid: 18929108

25. Gunny R, Yousry TA, Imaging anatomy of the vestibular and visual systems: Curr Opin Neurol, 2007; 20; 3-11, pmid: 17215682

26. Lagreze WA, Gaggl M, Weigel M, Retrobulbar optic nerve diameter measured by high-speed magnetic resonance imaging as a biomarker for axonal loss in glaucomatous optic atrophy: Invest Ophthalmol Vis Sci, 2009; 50; 4223-28, pmid: 19407026

27. Kashiwagi K, Okubo T, Tsukahara S, Association of magnetic resonance imaging of anterior optic pathway with glaucomatous visual field damage and optic disc cupping: J Glaucoma, 2004; 13; 189-95, pmid: 15118461

28. Iwata F, Patronas NJ, Caruso RC, Association of visual field, cup-disc ratio, and magnetic resonance imaging of optic chiasm: Arch Ophthalmol, 1997; 115; 729-32, pmid: 9194723

29. Pautler RG: NMR Biomed, 2004; 17; 595-601, pmid: 15761948

30. Watanabe T, Michaelis T, Frahm J: Magn Reson Med, 2001; 46; 424-29, pmid: 11550231

31. Berkowitz BA, Roberts R, Prognostic MRI biomarkers of treatment efficacy for retinopathy: NMR Biomed, 2008; 21; 957-67, pmid: 18729237

32. Calkins DJ, Horner PJ, Roberts R, Manganese-enhanced MRI of the DBA/2J mouse model of hereditary glaucoma: Invest Ophthalmol Vis Sci, 2008; 49; 5083-88, pmid: 18552381

33. Chan KC, Fu QL, Hui ES: Neuroimage, 2008; 40; 1166-74, pmid: 18272401

34. Dandona L, Hendrickson A, Quigley HA, Selective effects of experimental glaucoma on axonal transport by retinal ganglion cells to the dorsal lateral geniculate nucleus: Invest Ophthalmol Vis Sci, 1991; 32; 1593-99, pmid: 1707861

35. Rofsky NM, Earls JP, Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging: Magn Reson Imaging Clin N Am, 1996; 4; 73-85, pmid: 8673718

36. Tofts PS, Porchia A, Jin Y, Toward clinical application of manganese-enhanced MRI of retinal function: Brain Res Bull, 2010; 81; 333-38, pmid: 19524028

37. Olsen O, Thuen M, Berry M, Axon tracing in the adult rat optic nerve and tract after intravitreal injection of MnDPDP using a semiautomatic segmentation technique: J Magn Reson Imaging, 2008; 27; 34-42, pmid: 18157895

38. Hagmann P, Jonasson L, Maeder P, Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond: Radiographics, 2006; 26(Suppl 1); S205-23, pmid: 17050517

39. Xu J, Sun SW, Naismith RT, Assessing optic nerve pathology with diffusion MRI: from mouse to human: NMR Biomed, 2008; 21; 928-40, pmid: 18756587

40. Hui ES, Fu QL, So KF, Wu EX, Diffusion tensor MR study of optic nerve degeneration in glaucoma: Conf Proc IEEE Eng Med Biol Soc, 2007; 2007; 4312-15, pmid: 18002956

41. Garaci FG, Bolacchi F, Cerulli A: Radiology, 2009; 252; 496-501, pmid: 19435941

42. Duncan RO, Sample PA, Weinreb RN, Retinotopic organization of primary visual cortex in glaucoma: Comparing fMRI measurements of cortical function with visual field loss: Prog Retin Eye Res, 2007; 26; 38-56, pmid: 17126063

43. Qing G, Zhang S, Wang B, Wang NL, Functional MRI signal changes in primary visual cortex corresponding to the central normal visual field of patients with primary open angle glaucoma: Invest Ophthalmol Vis Sci, 2010; 51(9); 4627-34, pmid: 20357191

44. Jansen JF, Backes WH, Nicolay K, Kooi ME, 1H MR spectroscopy of the brain: absolute quantification of metabolites: Radiology, 2006; 240; 318-32, pmid: 16864664

45. Labak M, Foniok T, Kirk D, Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer;s disease: Acta Neurochir Suppl, 2010; 106; 177-81, pmid: 19812944

46. Auer DP: Exp Gerontol, 2009; 44; 4-9, pmid: 18805476

47. Ramli N, Rahmat K, Azmi K, Chong HT, The past, present and future of imaging in multiple sclerosis: J Clin Neurosci, 2010; 17; 422-27, pmid: 20167498

48. Chan KC, So KF, Wu EX, Proton magnetic resonance spectroscopy revealed choline reduction in the visual cortex in an experimental model of chronic glaucoma: Exp Eye Res, 2009; 88; 65-70, pmid: 18992243

49. Boucard CC, Hoogduin JM, van der GJ, Cornelissen FW, Occipital proton magnetic resonance spectroscopy (1H-MRS) reveals normal metabolite concentrations in retinal visual field defects: PLoS One, 2007; 2; e222, pmid: 17311099

50. Ngumah QC, Buchthal SD, Dacheux RF, Longitudinal non-invasive proton NMR spectroscopy measurement of vitreous lactate in a rabbit model of ocular hypertension: Exp Eye Res, 2006; 83; 390-400, pmid: 16631164

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750